Stimulation of Mammary Tumorigenesis and Suppression of Uterine Adenomyosis by Temporary Inhibition of Pituitary Prolactin Secretion during Youth in Mice
Abstract
The effects of daily subcutaneous injections of 0.2 mg CB-154 (bromocriptine-mesilate), a potent suppressor of pituitary prolactin secretion, between 4 and 11 weeks of age on the occurrence of spontaneous mammary tumors and adenomyosis, a hyperplasia of endometrial tissue, were studied in the SHN strain of virgin mice. While there was little difference in mammary tumor incidence between experimental and control mice until 9 months of age, mammary tumor incidence in the experimental mice given CB-154 was significantly enhanced and surpassed that in the control after 10 months; 25 (53.2%), 31 (66.0%), and 36 (75.5%) of 47 experimental mice and 20 (27.5%), 23 (33.3%), and 34 (49.3%) of 69 control mice developed mammary tumors at 10, 11, and 12 months of age, respectively. In contrast, no adenomyosis appeared in 39 experimental mice at necropsy at 12 months of age, while 15 (46.9%) of 32 control mice developed it. Furthermore, five mice (15.6%) of the control had numerous subserosal nodules, an advanced state of adenomyosis. No significant correlation was observed in the control mice between the occurrence of mammary tumors and that of adenomyosis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Inhibition of pituitary prolactin secretion during youth in mice suppressed induction of adenomyosis, suggesting a potential role of prolactin.
“but inhibition of pituitary prolactin secretion during youth in mice suppressed the induction of adenomyosis [60], suggesting the potential role of prolactin in the pathogenesis of adenomyosis.”
From The Pathogenesis of Adenomyosis vis-à-vis Endometriosis (2020) · cites this paper as [60]
Cited by
Sorted by citations
Adenomyosis: Mechanisms and Pathogenesis
Zhai, J., Vannuccini, S., Petraglia, F., & Giudice, L. C. (2020) · Seminars in Reproductive Medicine · doi:10.1055/s-0040-1716687 · Cited by 331 · see citing works
The Pathogenesis of Adenomyosis vis-à-vis Endometriosis
Guo, S.-W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020485 · Cited by 165 · see citing works
Greaves, P. (2012) · Elsevier eBooks · doi:10.1016/b978-0-444-53856-7.00012-9 · Cited by 97 · see citing works
Animal model of uterine adenomyosis: Is prolactin a potent inducer of adenomyosis in mice?
Mori, T., Singtripop, T., & Kawashima, S. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)90258-s · Cited by 60 · see citing works
Self-citationMatalliotakis, I., Kourtis, A., & Panidis, D. (2003) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(02)00053-0 · Cited by 66 · see citing works
Marquardt, R. M., Jeong, J., & Fazleabas, A. T. (2020) · Seminars in Reproductive Medicine · doi:10.1055/s-0040-1718741 · Cited by 26 · see citing works
“Early on, the discovery was made that inhibition of pituitary function suppressed natural adenomyosis development and that intrauterine pituitary transplantation caused adenomyosis development [32,33].”
BackgroundNagasawa, H., Noguchi, Y., Mori, T., Niki, K., & Namiki, H. (1985) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(85)90250-0 · Cited by 21 · see citing works
Self-citationToxicologic Pathology of the Reproductive System
Woldemeskel, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804239-7.00064-0 · Cited by 18 · see citing works
Multiple Endocrine Syndrome in SHN Mice: Mammary Tumors and Uterine Adenomyosis
Mori, T., & Nagasawa, H. (1989) · Springer eBooks · doi:10.1007/978-94-009-1091-1_18 · Cited by 12 · see citing works
Self-citationInteractive responses to diethylstilboestrol in C3H mice
Greenman, D. L., & Delongchamp, R. R. (1986) · Food and Chemical Toxicology · doi:10.1016/0278-6915(86)90320-0 · Cited by 11 · see citing works
Toxicologic pathology of the reproductive system
Wangikar, P. B., Ahmed, T., & Vangala, S. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-382032-7.10076-1 · Cited by 11 · see citing works
Exploring the Endocrine Mechanisms in Adenomyosis: From Pathogenesis to Therapies
d’Otreppe, J., Patiño-García, D., Piekos, P., de Codt, M., Manavella, D. D., Courtoy, G. E., & Orellana, R. (2024) · Endocrines · doi:10.3390/endocrines5010004 · Cited by 8 · see citing works
“Thus, treatments known to reduce OTR expression, like deacetylase inhibitors and andrographolides, hold potential in treating ADM [70].”
BackgroundKhan, Z., & Stewart, E. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00026-3 · Cited by 7 · see citing works
The Pathophysiology of Adenomyosis
Habiba, M. A., Benagiano, G., & Brosens, I. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-13012-5_3 · Cited by 5 · see citing works
Khan, Z., & Stewart, E. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2758-2.00027-5 · Cited by 5 · see citing works
Toxicologic pathology of the reproductive system
Woldemeskel, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89773-0.00064-3 · Cited by 4 · see citing works
Endometrium Derived Stem Cells as Potential Candidates in Nervous System Repair
Yan, Y., Wang, X., & Zhu, G. (2022) · Annals of Biomedical Engineering · doi:10.1007/s10439-022-02909-0 · Cited by 3 · see citing works
Xu, S., Xin, Y., Lv, F., Hu, X., & Xiao, R.-P. (2026) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/csb-2025-5885 · Cited by 1 · see citing works
“进 一步研究发现 , 随着病变进展 , 垂体移植诱导的腺肌症 小鼠模型子宫组织中 PRLR 的 mRNA 表达逐渐升高 [82] , 而在小鼠性成熟早期阶段暂时抑制垂体 PRL 分泌则可 一定程度上降低成年后腺肌症的发生率和病变严重程 度 [83] .”
Stewart, E. A. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4907-4.00025-5 · Cited by 1 · see citing works
Greaves, P. (2000) · Elsevier eBooks · doi:10.1016/b978-044450514-9/50011-5
- Authors
- Nagasawa, H., & Mori, T.
- Affiliations
- Meiji University (JP)
- The University of Tokyo (JP)
- Venue
- Experimental Biology and Medicine
- Publisher
- Frontiers Media SA
- Published
- 1982-11-01
- Volume
- 171
- Issue
- 2
- Pages
- 164-167
- ISSN
- 0071-3384 (ISSN-L)
- 1535-3702
- 1535-3699
- OpenAlex
- W2103617431
- Cited by
- 20
- References
- 0
- Citations by year
- 2026: 1 · 2024: 1 · 2022: 2 · 2020: 3 · 2019: 1 · 2017: 1 · 2015: 1 · 2013: 1 · 2012: 1
- FWCI
- 0.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Experimental Biology and Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Keywords
- mammary carcinogenesis, adenomyosis, prolactin secretion, bromocriptine, CB-154, pituitary gland, endometrial hyperplasia, spontaneous mammary tumors, SHN mice
- MeSH terms
- Age Factors, Animals, Bromocriptine, Endometriosis, Female, Mammary Neoplasms, Experimental, Mice, Inbred Strains, Prolactin, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
